ChartMillAugust 6, 2026 at 8:53 AM NY2 Months Ago

Collegium Pharmaceutical (NASDAQ:COLL) Tumbles on Revenue Miss and Lowered Guidance

COLLCollegium Pharmaceutical, Inc.

Collegium Pharma Q2 beats EPS but misses revenue; cuts FY product revenue guidance, stock falls ~11%. ADHD growth offsets pain portfolio weakness.

What This Story Means

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site: ChartMill